Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
about
Recent progress in pancreatic cancerEmerging concepts in pancreatic cancer medicine: targeting the tumor stromaCurcumin AntiCancer Studies in Pancreatic CancerPrognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysisSystemic Chemotherapy in Advanced Pancreatic CancerPharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveLocal Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A ReviewCurrent therapeutic strategies for advanced pancreatic cancer: A review for cliniciansManagement of pancreatic cancer in the elderlyGemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.Novel agents for advanced pancreatic cancerPerspectives in the treatment of pancreatic adenocarcinomaPancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesImaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted NanovesiclesSystemic treatment for inoperable pancreatic adenocarcinoma: review and updatePancreatic adenocarcinoma: treating a systemic disease with systemic therapyPersistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinomaSystemic therapies for pancreatic cancer--the role of pharmacogeneticsFOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerMetastatic pancreatic cancer: Is there a light at the end of the tunnel?Advances in chemotherapy for pancreatic cancerIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineGemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I studyNeoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials.Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
P2860
Q24626346-CC5E8CDA-E2D1-4747-9ED0-47C1E9C565CBQ24627664-C597C4EB-4E50-4969-8D0E-8340AA66DE85Q26738714-627C73F3-E4AA-4444-BB04-4028D402811FQ26747108-EBA1DE38-F5E4-41CC-8865-F7560D5F3689Q26750440-3EF77468-AD7D-4F44-AA39-B811EF4E66CCQ26752368-0F3F4BA0-A9A8-4EC4-AA56-8B63FC4F6907Q26765288-90046E15-6BD4-421F-9E12-D0C68E98E0F7Q26767041-A3823BAE-3506-41C2-8A75-249FB51CAD13Q26774639-77C88AD8-CF1F-450D-8E09-5A78CAF027D3Q26786174-94BE6765-9630-4C4F-AD1D-006A060EC926Q26787087-B3F1E49F-D279-40AA-92C1-B8EC830DED35Q26797248-F43593A7-4F4E-410C-A6A5-D550ACB6DADCQ26799714-57B5E8BB-0BF2-4C51-A2DD-7666EBD667E8Q26828959-0CA99BF5-5460-467A-B4E8-5844BB733481Q26830913-B3E1F363-A668-4039-8F14-EEE149B44951Q27008346-334AC44B-252A-44D0-BE0C-A4075E2E61B7Q27012236-CC37B686-C8E6-47DB-A6C0-8F8208C4AC33Q27021716-58234F43-57D4-49C0-BEAA-3905046D077EQ28075540-7867BC0B-84F1-4235-B651-3535AA9FD7B0Q28082919-2B81A00F-BF28-49CC-B948-D73B0C149DEDQ28085711-577D4B69-BF22-4877-9245-95D985E89971Q29616728-3258282C-866D-4F48-A2C7-A16B802C5773Q33350085-2B34B7A8-A359-490B-8EBD-AF39E049CC53Q33388392-D9817862-A7D9-4F01-9C9F-3E97F2700908Q33394594-D6ABCE88-46D9-4F2E-8FB6-33A137A2C1B5Q33395577-D044B9EA-755A-459B-A643-1D158CF9BE9FQ33396763-3A4ECBD9-E918-46C3-93A1-96023A24B483Q33400095-42127036-9726-4C5A-A6C7-35AE3087DE3DQ33401071-635FAE59-22A3-4D45-A964-25EAA46B1CE6Q33401816-2A8DC694-C69C-4478-B289-6910E30BAA51Q33402401-3DAAB560-9A4E-462C-83E7-F8AD8FE6D71BQ33402598-7E1396C5-DC0A-4071-867E-4D2266419A2DQ33403498-672C87AB-96FD-4EED-A782-94EF749082B6Q33414629-62073A8E-5C24-4EE6-B2CB-825FE5BAC9BAQ33415922-E1A61288-C055-4ABA-B8D3-1411B67D5805Q33417372-D9823682-F08B-46BB-A677-9846A8CF757DQ33418472-B8AB3788-A0CC-4B73-A0F4-72CB7227313AQ33418849-14EF9274-5134-4CF3-BDE8-1B88039FE3F0Q33427177-5DDF9EDE-E497-4384-875B-C7B770DB6A7EQ33432931-A2CE4B27-345B-46BB-8AFC-66835B4CB1ED
P2860
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase III, randomized study of ...... rn Cooperative Oncology Group.
@ast
Phase III, randomized study of ...... rn Cooperative Oncology Group.
@en
type
label
Phase III, randomized study of ...... rn Cooperative Oncology Group.
@ast
Phase III, randomized study of ...... rn Cooperative Oncology Group.
@en
prefLabel
Phase III, randomized study of ...... rn Cooperative Oncology Group.
@ast
Phase III, randomized study of ...... rn Cooperative Oncology Group.
@en
P2093
P2860
P356
P1476
Phase III, randomized study of ...... rn Cooperative Oncology Group.
@en
P2093
Al Bowen Benson
Daniel Haller
David Cella
Edith Mitchell
Elizabeth Poplin
Howard Hochster
Jordan Berlin
Mace L Rothenberg
Paul Catalano
Peter O'Dwyer
P2860
P304
P356
10.1200/JCO.2008.20.9007
P407
P577
2009-07-06T00:00:00Z